Pfizer announced that its key vaccine portfolio, including Prevnar, Abrysvo, and Comirnaty, experienced sales declines in the third quarter of 2025, reflecting ongoing challenges in the U.S. immunization market.

Despite continued global demand, the company’s overall vaccine performance was impacted by softer uptake in the United States. Among Pfizer’s leading vaccines, only TicoVac, its tick-borne encephalitis shot, recorded a sales increase for the quarter ended September 30, 2025.

Comirnaty, Pfizer’s COVID-19 prevention vaccine, reported global sales of $1.15 billion, marking a 19 per cent decline compared to the same period last year. The Prevnar pneumococcal vaccine franchise recorded a 3 per cent decrease to $1.7 billion, while Abrysvo, the company’s respiratory syncytial virus (RSV) vaccine, saw sales decline by 22 per cent to $279 million.

However, ex-U.S. markets provided a bright spot for both Prevnar and Abrysvo. Sales of Abrysvo outside the U.S. surged by 75 per cent, highlighting growing international adoption and confidence in the vaccine’s clinical value.

Pfizer reaffirmed its commitment to strengthening its global vaccine portfolio through ongoing research, innovation, and expansion into emerging markets, even as it navigates near-term headwinds in the U.S. immunization landscape.